MICS+aspheric IOL = fewer corneal changes

Article

Microincision cataract surgery (MICS) with implantation of an aspheric intraocular lens (IOL) through a 1.8 mm incision can minimize surgically-induced corneal and ocular aberrations and improve optical performance, according to a French study.

Microincision cataract surgery (MICS) with implantation of an aspheric intraocular lens (IOL) through a 1.8 mm incision can minimize surgically-induced corneal and ocular aberrations and improve optical performance, according to a French study.

Alexandre Denoyer and co-workers from Bretonneau University Hospital, France evaluated the postoperative corneal and ocular aberrations of 20 subjects following MICS with implantation of the aspheric MI60 IOL (Bausch & Lomb) through a 1.8 mm incision in one eye and through a 2.8 mm incision in the other eye.

The researchers found that changes in the corneal topography and aberrations were lower in the MICS group than in the other eye (p<0.05), as were the total ocular wavefront aberrations (p<0.05). Best corrected visual acuity and subjective visual comfort were similar in both groups.

Dr Denoyer concluded that MICS with implantation of an aspheric IOL can help minimize surgically-induced corneal changes.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.